Sentences with phrase «biotech stocks»

We've wondered whether, after years of betting on biotech stocks to fall, he'd undergone a conversion or was using his knowledge to game the field.

The volatility of biotech stocks provides an opportunity for investors.

Others argue that this may just be a natural correction for biotech stocks after a remarkable five - year bull run, which has been the greatest in the industry's history.

So far, 2018 is shaping up to be a banner year for a handful of small - cap biotech stocks.

Point blank: The ETF route may not be as exciting as owning individual biotech stocks, but it comes with a more reasonable level of risk and respectable growth prospects.

Several biotech stocks started off with a bang in 2018.

Within this context, it may make sense for some long - term investors to consider how biotech stocks may fit into their portfolio.

Are any of these hot biotech stocks decent picks after their huge gains?

Are you interested in putting a few biotech stocks on your holiday wish list?

Which biotech stocks do we think are smart picks for investors who are willing to accept some risk?

With these facts in mind, let's consider if this top biotech stock is worth picking up after this sudden decline.

Some of you may not be aware that a few months ago I wrote that I was buying stocks for the first time in 12 years, and specifically smaller, transformational biotech stocks.

On occasion, I notice biotech stocks that pop up with a market cap lower than their net cash on hand.

If biotech stocks are all the rage six months later, he'll probably move his money again, perhaps before he has even experienced significant appreciation in his internet investments.

One easy way is to buy into an exchange - traded fund, or ETF, that owns a huge basket of biotech stocks.

And within a span of six weeks this fall, Hillary Clinton caused a drop in biotech stocks with a tweet calling for greater regulation of drug prices, then single - handedly tanked stocks of private - corrections companies when she tweeted about prison reform.

FDA Insider Alerts uses a proven 3 - step process to identify biotech stocks with upside potential weeks before they skyrocket.

A day after Collins was heard off the House floor discussing the possible sale of an Australian biotech stock, the company issued a news release further confirming its experimental treatment for multiple sclerosis had failed in clinical trials.

After all, a tweet from then - Democratic presidential candidate Hillary Clinton about price gouging in the drug market sent biotech stocks tanking in September 2015.

With biotech stocks at their highest level since January, one strategist thinks a Donald Trump presidential win could send them even higher.

The larger - than - expected loss appears to be the primary reason shares fell today, though it's possible Novavax's stock is tanking simply because biotech stocks in general are having a rough day.

Low - priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue.

The next step is when biologists and biotech stock market analysts start weighing in, predicting the usefulness (and investor appeal) of the drug combination, even when there are plenty of warning signs that it won't work.

After a couple of tough years in 2015 and 2016, biotech stocks made a comeback in 2017 and are off to a strong start in 2018, with the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) up 10 % year to date already.

Most biotech stocks are subject to the risk of failed drug trials, which can decimate your position without any warning.

Given revenue uncertainty, investors should treat biotech stocks like stock options, and big pharma equities like ETFs.

Several major biotech stocks fell after the U.S. Food and Drug Administration made it easier for the public to search for drug side effects through a database.

«My fondest dream,» he wrote in one recent commentary, «is that I will give my gold coins to my great - great grandkids some 70 - 80 years from now, and they will be rather embarrassed that their Papa John bought all that much of that barbarous yellow metal instead of more biotech stocks.

Hillary Clinton has been considered one of the biggest threats to biotech investors ever since September 2015, when she pushed biotech stocks into a bear market with a single tweet about cracking down on drug price hikes that cost the sector $ 40 billion in market value.

To short biotech stocks, Shkreli would have had to borrow shares in biotech companies, sell them, and ideally buy them back and return them at a lower price in order to pocket the difference.

After racking up losses while running hedge fund firm MSMB Capital Management, which made bets against biotech stocks, Shkreli formed a biotech company of his own called Retrophin (RTRX) in 2011.

Pharma and biotech stocks swooned recently (the S&P Pharmaceuticals Select Industry Index is down 25 % in the last three months), largely on concerns about greater drug price regulation.

The entire biopharma industry got some collective heartburn yesterday after President - elect Donald Trump's comments that drug makers are «getting away with murder» on pricing sent biotech stocks plummeting.

For example, if a certain biotech stock gains FDA approval for a blockbuster drug, the move to the upside could be magnified because the reported news catches the eye of investors.

We've been trading a lot of biotech stocks lately, so it must have been a Freudian slip.

Discover three blue - chip biotech stocks you should keep your eye on in 2016.

Where there is more uncertainty is in small and mid-cap biotech stocks: «Biotech is just rife with speculation — that is not what we do,» says CT Fitzpatrick, CEO of Vulcan Value Partners.

CEO backs down following drug cost hike The skittish stock market place took another tumble — and plunging biotech stocks led the way lower.

However, if there's a company with Nike - like return potential in the works, I believe it to be budding biotech stock Ligand Pharmaceuticals.

While I understand the trepidation, I think it's a mistake to simply ignore investing in biotech completely, as winning biotech stock returns can be extraordinary.

With the likely beginning of solid product - based recurring revenue to complement its cadre of milestone payments, Ionis looks like the perfect diversified biotech stock to consider adding to your portfolio.

More generally, many biotech stocks bounced due to investor opinion that they had taken too large a hit in recent months.

The SPDR uses more of an equal - weight approach, using solely biotech stocks and not limiting exposure to stocks that trade on any one particular exchange.

Ligand isn't like a traditional biotech stock in that it doesn't spend years or decades bringing drugs from the discovery stage to pharmacy shelves, which is an exceptionally risky boom - or - bust model.

So while it's probably unwise to back up the truck with this speculative biotech stock, I do think it's worth owning a small position in case oliceridine hits pay dirt next year.

Brian Feroldi (Supernus Pharmaceuticals): Most small - cap biotech stocks barely generate any revenue at all, let alone profits.

Thus, when biotech stocks perform well, so does the XBI.

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

Conflicting statements from the Trump administration have made owning biotech stocks feel like a roller - coaster ride in recent weeks, but there are a few stocks I'd happily buy and hold despite the sway of political uncertainty.